Bio-Techne Corp (TECH) News & EventsTECHBio-Techne Corp

Bio-Techne Opens GMP Small Molecule Manufacturing Facility in Bristol, UK

Bio-Techne announced the opening of a new manufacturing facility for Good Manufacturing Practice - GMP - grade small molecules in Bristol, U.K. The purpose-built 10,000-square-foot Bristol facility features five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling. Together with the company's recombinant protein manufacturing operations in Minneapolis, Minnesota, its GMP capabilities in St Paul, and its strategic relationship with Wilson Wolf Corporation, a manufacturer of cell culture devices, Bio-Techne offers a portfolio of GMP proteins, GMP small molecules, GMP cell media, custom manufacturing services, analytical solutions, and process development support. The Bristol facility is fully operational and is manufacturing GMP-grade small molecules.

Bio-Techne Shareholders Approve Merck Acquisition Agreement

Bio-Techne announced that shareholders voted to approve and adopt the definitive agreement under which Merck KGaA, Darmstadt, Germany proposes to acquire Bio-Techne at a Special Meeting of Shareholders held today. The final voting results, as certified by the independent inspector of elections, will be reported in a Form 8-K filed with the SEC. In addition to shareholder approval, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the proposed transaction expired at 11:59 p.m., Eastern Time, on September 18. Bio-Techne continues to expect the transaction to close by late 2026 or early 2027, subject to satisfaction of customary closing conditions, including receipt of remaining required regulatory approvals.

Trump Considers New Semiconductor Tariffs Impacting Multiple Companies

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.SEMICONDUCTOR TARIFFS:The Trump administration is considering broad new semiconductor tariffs that could extend to chip-containing products such as laptops and data-center servers, potentially raising AI infrastructure costs while linking tariff relief to U.S. manufacturing investment, Politico's Ari Hawkins and Gabby Miller. The administration is also mulling a phase-in period for the new tariffs, people familiar with the matter say. Publicly traded companies in the space include AMD, Intel, Marvell, Microchip, Micron, Nvidia, Qualcommand Texas Instruments.GRID EQUIPMENT:President Trump signed an emergency order that bars the U.S. purchase or installation of certain foreign-made, bulk-power system electrical equipment, and associated software, where it could pose cybersecurity or operational risks, Jennifer Dlouhy of Bloomberg, citing a White House official. Publicly traded companies in the solar space include Array Technologies, Canadian Solar, Emeren, Enphase Energy, FTC Solar, First Solar, JinkoSolar, Maxeon Solar, Shoals Technologies, SolarEdge, SunPowerand Sunrun.DRUG PRICING DEALS:The Trump administration is set to announce new drug pricing agreements with several midsized biotechs, trading Medicaid discounts tied to international prices for exemptions from certain Medicare pricing pilots and, in some cases, tariff relief, Bloomberg's Nyah Phengsitthy, Rachel Cohrs Zhang, and Madison Muller. Publicly traded companies in the space include Neurocrine Biosciences, Exelixis, Alnylam, BioMarin, United Therapeutics, Ionis, Bio-Techne, and Alkermes.DATA-SHARING DEALS:The Trump administration has struck data-sharing deals with OpenAI, Google, Meta, Amazon, and other tech companies to track how AI is affecting jobs and hiring, Courtenay Brown of Axios. The Labor Department has signed memorandums of understanding with "a lot of these tech companies," acting Labor Secretary Keith Sonderling told Axios.